SLN.L Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jan 1970 @ 01:00):

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications...

Stats
Dagens volum	913 528
Gjennomsnittsvolum	104 775
Markedsverdi	0.00
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.110
ATR14	£0 (0.00%)

Silence Therapeutics PLC Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Silence Therapeutics PLC Økonomi

Annual	2020
Omsetning:	£5.48M
Bruttogevinst:	£1.72M (31.34 %)
EPS:	£-0.398

FY	2020
Omsetning:	£5.48M
Bruttogevinst:	£1.72M (31.34 %)
EPS:	£-0.398

FY	2019
Omsetning:	£244 000
Bruttogevinst:	£0.00 (0.00 %)
EPS:	£-0.261

FY	2018
Omsetning:	£0.00
Bruttogevinst:	£0.00 (0.00 %)
EPS:	£-0.262

Financial Reports:

No articles found.

Silence Therapeutics PLC

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.